Salute e Benessere

EVERSANA Completes Integration of Healthware Group and Strengthens Its Global…

EVERSANA INTOUCH Healthware joins five full-service affiliates and four specialty affiliates serving clients across the globe with world-class strategy, next-generation branding and creative, and innovative solutions to propel the future of life science marketing. Combined, the network helps pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, and solve unique geographic and market-specific challenges. EVERSANA INTOUCH Healthware joins...
PR Newswire
15/04/2024

TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE…

Parkinson's disease is a complex neurodegenerative disorder that affects more than 10 million worldwide, characterized by the progressive loss of dopamine-producing neurons in the brain. This debilitating condition manifests primarily through a range of motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor symptoms which can include cognitive impairment and mood disorders. Symptoms usually appear when between 60%-80% of dopaminergic neurons are already lost, so...
PR Newswire
15/04/2024

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1…

The study plans for the enrolment of 12 patients in 5 French clinical centersFirst study results expected in Q3 2024This study will enable an evaluation of the intravenous administration of phages, particularly adapted to targeting indications with very high medical stakes. Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30am CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135),today announces the enrolment of the 1 stpatient in the phase 1 clinical...
Nasdaq GlobeNewswire
15/04/2024

Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting

Oslo, April 15, 2024:In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting rights without voting instructions for 9,063,854 shares, representing 26.34% of the total voting rights in the company. The proxies are only valid for the Annual General Meeting on April 18, 2024. This information is subject of the disclosure requirements pursuant to section 5-12 of the...
Nasdaq GlobeNewswire
15/04/2024

[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary…

Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma Data from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meeting Basel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with...
Nasdaq GlobeNewswire
15/04/2024

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

DUBLIN, April 14, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of the European Bone Marrow Transplant Meeting (EBMT), Europe's largest annual congress in blood and bone marrow transplantation and cellular therapies. In recognition of 30 years since clinicians first used ECP to successfully treat chronic GvHD,1…
PR Newswire
14/04/2024

Pioneering Cutting-Edge Technologies: High-End Medical Imaging Developer VITAL…

Revolutionizing conventional CT technology, PCCT adopts photon counting-based tomography using CZT (Cadmium Zinc Telluride, CdZnTe) detectors for photon counting and energy analysis, which allows accurate measurement and recording of each X-ray photon that passes through to reveal unparalleled details of internal structures. PCCT's direct imaging innovation transcends conventional CT imaging constraints of crosstalk, electronic noise, and energy mixing, significantly enhancing image resolution…
PR Newswire
13/04/2024

STD Testing Market Projected to Reach $14.11 billion by 2030 - Exclusive Report…

Sexually transmitted infection (STI) testing is experiencing remarkable growth, propelled by an increase in public awareness, government initiatives aimed at preventing the spread of STIs, and significant advancements in diagnostic technologies. This surge is supported by the critical role of STD testing in safeguarding individual health, containing disease spread, and ensuring timely intervention. The diagnostic methods, including blood and urine tests, swabs, and physical exams, expand to…
PR Newswire
13/04/2024

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,599,938 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
12/04/2024

Nexstim Plc Resolved on a New Stock Option Plan 2024H

Company Announcement, Helsinki, 12 April 2024 at 9 PM (EEST) Nexstim Plc Resolved on a New Stock Option Plan 2024H Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that the Board of Directors of Nexstim resolved on 12 April, 2024, to launch a new stock option plan 2024H aimed at the Board of Directors of the Company by virtue of an authorization granted by the Annual General Meeting of Shareholders of the company on March 28, 2024, and according to the AGM…
Nasdaq GlobeNewswire
12/04/2024

Ceiling Fan Market to Reach $16.8 billion, Globally, by 2033 at 4.3% CAGR…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06366 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A06366 Drivers, restraints, and opportunities A significant growth in the expenditure on home renovation/remodeling projects among the millennials and the baby boomers especially in developed economies like the U.S. is fueling the demand for the décor ceiling fans. Moreover, the...
PR Newswire
12/04/2024

Apheresis Market Worth $3.9 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950 Browse in-depth TOC on "Apheresis Market" 376 - Tables 65 - Figures 343 - Pages Apheresis Market Scope: Therapeutic apheresis is the fastest growing segment in the apheresis market in 2023. Based on procedure, the apheresis market is segmented into automated blood collection...
PR Newswire
12/04/2024

Power Tools Market worth $45.5 billion by 2029 - Exclusive Report by…

Browse in-depth TOC on "Power Tools Market" Browse in-depth TOC on "Power Tools Market" 175 – Tables 64 – Figures 239 – Pages Power Tools Market Report Scope: Drilling and Fastening Tools segment is expected to grow at the highest CAGR during the forecast period. The drilling and fastening tools segment are expected to grow at the highest CAGR during the forecast period. Drilling and fastening tools are extensively used across industrial sectors due to their versatility...
PR Newswire
12/04/2024

Clarification of guidance for revenue and lower than expected operating profit…

ANNOUNCEMENT NO. 261 Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial yearAccording to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98.9 million and in the first nine months of 2023/24 DKK 298.2 million.Based on the development in the third quarter of 2023/24 and the expectations for the remaining part of the financial year, expectations for revenue for the 2023/24 financial year are clarified...
Nasdaq GlobeNewswire
12/04/2024

BioSenic provides further information on its restructuring plan

PRESS RELEASE - PRIVILEGED INFORMATIONMont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET –BioSenic(Euronext Brussels and Paris: BIOS),the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position and (ii) links to the Company's website to consult...
Nasdaq GlobeNewswire
12/04/2024

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical…

Cbio A/S –Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates. Ulrik Cordes, Founder & CEO of Cbio, stated: “2023 was another great year for Cbio. We finalized the preclinical development of our lead T-cell therapy asset, novoleucel and made considerable progress in preparing for our upcoming phase I/II clinical trial at Karolinska, where we will treat 20 patients with late-stage cervical cancer.Ulrik Cordes continues: “Our top...
Nasdaq GlobeNewswire
12/04/2024

Recruitment milestone reached in Diamyd® Phase 3 trial

DIAGNODE-3, being the first ever precision medicine Phase 3 trial in type 1 diabetes, is ongoing in eight European countries and in the United States. The trial specifically enrols patients that carry the genetic HLA DR3-DQ2 haplotype, a genetic subgroup of type 1 diabetes that in previous trials has been associated with positive clinical response to Diamyd® treatment. The antigen-specific immunotherapy Diamyd® was in February 2024 granted Fast Track designation by the FDA and has previously…
PR Newswire
12/04/2024

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary…

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron's annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024.AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial...
Nasdaq GlobeNewswire
12/04/2024

Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data

RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients with a preserved ejection fraction (HFpEF). However, the results confirmed the importance of selecting patients with characteristics likely to benefit from atrial shunting versus those who will not. RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients...
PR Newswire
12/04/2024

Human Organoids Market Projected to Reach $2,124.91 million by 2030 - Exclusive…

Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care. These small and powerful organ models are transforming the approach to disease modeling, drug discovery, and personalized medicine by closely mimicking human physiological responses at a cellular level. With their unique ability to replicate human organ structure, functionality, and genetic diversity…
PR Newswire
12/04/2024

Endo, Inc. Announces Pricing of $1.5 billion of Senior Secured Term Loan as Part…

Endo intends to use a portion of the net proceeds of the Term Loan, together with the proceeds from the Notes offering, the proceeds of the rights offerings under the Plan and cash on hand, to acquire substantially all of the assets of EIP and certain of its affiliates. EIP will use the sale proceeds to: (i) make settlement payments under the Plan, (ii) make cash distributions to first lien claimholders under the Plan, and (iii) pay certain professional fees. A portion of the proceeds will also…
PR Newswire
12/04/2024

Endo, Inc. Announces Pricing of $1.0 billion of Senior Secured Notes

With the proceeds of this offering, Endo International plc ("EIP") and its affiliated debtors will have obtained a portion of the financing required under the Fourth Amended Joint Chapter 11 Plan of Reorganization of EIP and its affiliated debtors (the "Plan"). Endo currently expects the Plan to be effective on or around April 23, 2024. Endo's initial capital structure is expected to consist of a $400.0 million senior secured five-year super-priority revolving credit facility…
PR Newswire
12/04/2024

Usher Syndrome Market to Exhibit Growth at a CAGR of 10.55% by 2034 |…

Key Takeaways from the Usher Syndrome Market Report Key Takeaways from the Usher Syndrome Market Report Discover which therapies are expected to grab the major Usher syndrome market share @Usher Syndrome Market Report Usher Syndrome Overview Usher syndrome stands as the most prevalent deaf-blind syndrome, affecting half of those with deaf-blindness below the age of 65. This condition, rooted in genetics, manifests as a combination of hearing loss, retinopathy, and vestibular...
PR Newswire
11/04/2024

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical OfficerMont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer. Dr. Boon joins Nyxoah from the Thomas Jefferson...
Nasdaq GlobeNewswire
11/04/2024
Altri  Comunicati